Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 588210

Next Previous
Drug Profile

S 588210

Alternative Names: Multipeptide vaccine S-588210; S-488210/Montanide; S-488210/S-488211; S-488211/Montanide; S-588210

Latest Information Update: 28 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoTherapy Science
  • Developer AstraZeneca; OncoTherapy Science; Shionogi; University of Chicago
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bladder cancer
  • No development reported Cancer; Mesothelioma; Solid tumours

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Recurrent) in United Kingdom (Parenteral, Injection)
  • 25 Mar 2022 Phase-I/II clinical trials in Bladder cancer (Combination therapy) in United Kingdom (IV) (NCT04106115)
  • 22 Sep 2021 Shionogi completes the phase I trial in Solid tumors (Late-stage disease, Recurrent) in the United Kingdom (Parenteral) (NCT04316689)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top